Comparative Pharmacology
Head-to-head clinical analysis: HECTOROL versus VECTICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HECTOROL versus VECTICAL.
HECTOROL vs VECTICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
VECTICAL (calcitriol) is a vitamin D analog that binds to vitamin D receptors (VDRs) in target tissues, increasing intestinal calcium absorption, renal calcium reabsorption, and enhancing osteoclast activity to mobilize calcium from bone, thereby raising serum calcium levels.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
1-2 mcg orally twice daily, increased every 2-4 weeks based on serum calcium and PTH levels. Maximum dose: 4 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Mean terminal elimination half-life is approximately 3.7 hours (range 2.5–5.5 hours) in healthy adults. Clinically, steady-state is achieved within 2–3 days.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Primarily hepatobiliary (74%) and fecal (14%), with renal excretion accounting for <1% of the administered dose as unchanged drug. Enterohepatic recirculation occurs.
Category C
Category C
Vitamin D Analog
Vitamin D Analog